Metabolic relevance for N-hydroxy L-arginine reduction in estrogen-negative breast cancer cells

Abstract

We had shown N^w-hydroxy-L-arginine (NOHA) as a promising blood-based biomarker for estrogen-receptor-negative (ER^-) breast cancer (BC) that differentiates ER^- BC based on grade and molecular phenotype. In this in vitro study, we assessed the metabolic relevance for ER^- BC-specific NOHA modulation and correlated them with NOHA regulatory responses. This study aids future NOHA clinical utility in ER^- BC diagnosis and therapy management and would prove useful for potential drug discovery and development process.

Keywords: Biomarker; Estrogen negative breast cancer; Estrogen positive breast cancer; N w-hydroxy-L-arginine; Nitric oxide.